Analysis Report on Sainte Nutritional's RMB 467 Million Dividend Exceeding Net Profit

Based on the information I have collected, let me provide you with a detailed analysis report on Sainte Nutritional’s dividend event.

Sainte (Qingdao) Nutritional Health Technology Co., Ltd.
Sainte (Qingdao) Nutritional Health Technology Co., Ltd.
R&D, production and sales of special medical purpose formula food
Undergoing HKEX listing application
Qingdao City, Shandong Province
Approximately 20 years (founded in 2005) [1]

According to public information, Sainte Nutritional is implementing a total dividend plan of RMB 467 million, but this dividend amount exceeds the company’s annual net profit [2]. This event has triggered market concerns about the company’s capital chain security.

• The company is in the critical stage of its HKEX listing application
• Reports indicate that the company’s recent revenue and gross profit have both shown a downward trend
• The company’s main business is special medical purpose formula food, which belongs to the high-end niche market in the medical and health field

• Earnings Overdraft Risk
  : A dividend exceeding net profit may mean the company uses retained earnings from previous years; although not illegal, it may overdraft future dividend capacity
• Cash Flow Pressure
  : Large-scale dividends will directly consume the company’s cash reserves, possibly affecting the adequacy of daily operating funds
• Financing Dependence Risk
  : If dividend funds come from external financing, it will increase the company’s financial leverage and interest expense burden

• Reduced Operating Funds
  : The RMB 467 million dividend will significantly reduce the company’s cash and cash equivalents
• Short-term Debt Repayment Pressure
  : If the company has short-term debt, cash dividends may affect its repayment capacity
• Restricted Capital Expenditure
  : After the dividend, strategic expenditures such as R&D investment and capacity expansion may be cut

• Weakened Growth Momentum
  : The special medical formula food industry is highly competitive, requiring continuous R&D investment and market expansion
• Declined Risk Resistance Capacity
  : Reduced cash reserves will lower the company’s ability to cope with market fluctuations
• Hindered Expansion Plans
  : May affect the company’s ongoing projects or new market development plans

• May trigger potential investors’ doubts about the company’s financial health
• Need to explain the necessity of the dividend and its funding sources in detail in the prospectus
• May affect the IPO valuation level and financing scale

• HKEX may inquire about the situation where large dividends exceed net profit
• Need to provide sufficient rationality explanations and relevant financial data
• There is a possibility of being required to supplement disclosure information

• Obvious Policy Support
  : In recent years, it has received policy support from the national “Healthy China” strategy
• Growing Market Demand
  : With population aging and increased health awareness, market demand continues to grow
• Fierce Competitive Landscape
  : Fierce competition among domestic and foreign brands requires continuous R&D investment
• High Entry Barriers
  : Products need to obtain special medical purpose formula food registration certificates

• Raw material cost fluctuations
• Increasingly strict regulatory requirements
• High consumer education costs
• Large channel construction investments

, mainly based on the following considerations:

1. Large dividend scale (RMB 467 million)
2. The company is in a sensitive period of listing
3. Revenue and gross profit show a downward trend
4. The industry competition requires continuous investment

1. The company still has the expectation of listing financing
2. The special medical formula food industry has good prospects
3. The company has a certain historical accumulation (20 years of operation history)

1. The company’s specific net profit amount and dividend ratio
2. The specific source and composition of dividend funds
3. The company’s asset-liability ratio and cash flow status
4. Development strategy and capital needs for the next three years
5. Main shareholder structure and dividend motivation

1. Regulatory authorities’ review attitude towards this dividend
2. The company’s subsequent financial planning and capital arrangement
3. Whether the listing process will be affected
4. Institutional investors’ reactions to this matter

The event of Sainte Nutritional’s RMB 467 million dividend exceeding net profit is indeed worthy of attention. From a financial perspective, this approach carries certain capital chain pressure risks, especially against the background of the company’s declining revenue and gross profit. However, since the company is in the listing application stage, it is expected to replenish its capital strength through IPO financing in the future.

Need to pay attention to the company’s cash flow status after the dividend, short-term debt repayment capacity, and the implementation of future development strategies. Investors are advised to closely follow the company’s subsequent financial announcements and listing progress to obtain more complete information for evaluating investment value.

---

[1] Sainte Nutritional Official Website - Sainte Nutritional (https://www.sainte.com.cn)
[2] East Money Network - Relevant Reports on Sainte Nutritional (https://gbres.dfcfw.com)
[3] Yahoo Finance - Reports on Sainte Nutritional’s HKEX Listing Application (https://hk.finance.yahoo.com)